COMPANY

Rondo Therapeutics

HQ: Hayward, CA source · rondotx.com ↗ · West Coast

Keywords: antibody NGS oncology Non Small Cell Lung Cancer Cervical Cancer Head and Neck Squamous Cell Cancer Triple Negative Breast Cancer Urothelial Carcinoma Bladder Gastroesophageal Junction (GEJ) Adenocarcinoma Esophageal Squamous Cell Cancer Gastric Cancer RNDO-564

Location: Hayward, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Nov 17, 2025 Trial start 1: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 source ↗

Upcoming milestones

Feb 28, 2029 (ESTIMATED) · 1 · A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 · NCT07218003

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07218003	A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4	1	Enrolling by invitation	Nov 17, 2025	Feb 28, 2029 (estimated)